MODAG focuses on research and development of therapeutics and diagnostics for neurodegenerative diseases. It is a privately held company located at the Hochtechnologiepark Wendelsheim, Germany with additional Research & Development facilities in Munich and Göttingen. MODAG’s innovative approach offers a unique combination of early diagnosis and targeted disease-modifying therapies for severe neurological disorders.
MODAG´s collaborations with top-tier US and European research institutions, combined with the interdisciplinary research and development expertise of the founder´s and the management team, provide ideal conditions for the accelerated implementation into clinical applications. Built upon an extensive portfolio of patented active compounds, MODAG is developing a new oligomer modulator for Multiple System Atrophy (MSA) and other synucleinopathies such as Parkinson´s disease (PD) with the potential to deliver novel disease-modifying, first-in-class drugs with the potential to halt progression.
Company Details
- Employees
- 11
- Founded
- -
- Address
- Mikro-Forum Ring 3, Wendelsheim,rheinland-Pfalz 55234,germany
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.modag.net/
- Keywords
- anle138b, Parkinson, Multiple System Atrophy.
- HQ
- Wendelsheim, Rheinland-Pfalz
Modag Questions
Modag's website is https://www.modag.net/
Modag's LinkedIn profile is https://de.linkedin.com/company/modag
Modag has
11 employees.
View email and phone details for 11
employees at Modag.
Modag's industry is
Biotechnology Research
Modag's top competitors are
Catalym Gmbh,
Heidelberg Pharma Ag,
Cytena,
Unilabs Česko,
Tubulis Gmbh,
Atriva Therapeutics Gmbh,
Immatics,
Origenis Gmbh,
Aesku.group,
Advancecor Gmbh.
Modag's categories are Biotechnology Research
Modag's founding year is 2013
